Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Skye Bioscience, Inc. (SKYE)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0620-0.0080 (-11.43%)
At close: 03:56PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360

    SAN DIEGO, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today researchers from the University of Mississippi presented two Skye-sponsored studies at the 2021 American Association of Pharmaceutical Scientists Meeting (AAPS) PharmSci 360 held October 17-20, 2021, in Philadelphi

  • GlobeNewswire

    Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

    Exclusive sponsored research agreement with endocannabinoid research pioneersSAN DIEGO, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed a new exclusive sponsored research agreement with Emerald Health Biotechnology Espana SLU (“EHBE”), focused on developing and characterizing n

  • GlobeNewswire

    Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development

    SAN DIEGO, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has strengthened its management team with the appointment of Rhea Williams, MPH, as Head of Regulatory Affairs & Quality Assurance and Varun Khurana, PhD, as Senior Director of Research & Development. Rhea Williams, MPH, brings over 25 years of experience in drug development,

Advertisement
Advertisement